Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Larry Robbins’ Glenview Capital Manage...
Quick Take Genetron Holdings ( GTH ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an F-1 registration statement . The firm provides precision oncology diagnosis, monitoring and research services in China. GTH has grown but that growth is decelerating a...
– More sensitive and specific assays for vaginitis reduce the “incorrect, misguided or prolonged treatment” that can result from older, subjective testing methods – Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection o...
Usually, Once A Pattern Is Well Recognized It Stops Working I am hoping that I caught one before it really emerges. If we have, then we should generate good alpha. I believe I see the logic in it as well, just by examining my own "gut" over the course of the last few weeks. As we break i...
Hologic (NASDAQ: HOLX ) has agreed to sell its Cynosure medical aesthetics business to an affiliate of funds managed by Clayton, Dubilier & Rice for $205M in cash, although certain adjustments at closing will trim the proceeds to ~$138M. More news on: Hologic, Inc., Healthcare stocks...
NEW YORK , Nov. 20, 2019 /PRNewswire/ -- Clayton, Dubilier & Rice today announced an agreement under which CD&R-managed funds will acquire Cynosure, LLC, a leader in medical aesthetics systems and technologies, from Hologic, Inc. (NASDAQ:HOLX). Cynosure develops, manufac...
– Company Plans Accelerated Share Repurchase Program – Hologic, Inc. (Nasdaq: HOLX) announced today that it has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice f...
Breakthrough Artificial Intelligence-powered algorithm significantly reduces mammography exam read times without compromising image quality, sensitivity or accuracy 1 , 2 Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved 3DQ...
– First FDA-cleared test for this sexually transmitted bacterium can lead to earlier detection and appropriate treatment – A newly published study demonstrates clinical evidence for the effectiveness of a first-of-its-kind, FDA-cleared assay for the detection of the sexuall...
This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 11/05/2019. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...